Skip to NavigationSkip to content

Roche unveils strong combination treatment data in lung cancer

Published on 20/11/17 at 11:23am

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with Avastin and chemotherapy in the treatment of lung cancer.

The company revealed the findings of its Impower 150 trial into the use of Tecentriq, Avastin and chemotherapy in combination as a first-line treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC). According to Roche, they demonstrated a “statistically significant and clinically meaningful reduction” in the risk of disease progression or death compared to Avastin and chemotherapy alone.

“We are extremely encouraged by these results and will submit these data to health authorities globally with the goal of bringing a potential new standard of care for the initial treatment of lung cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “In addition to first-line NSCLC, we are testing the ability of Tecentriq and Avastin to enhance the potential of the immune system to combat a broad range of other cancers.”

The company did note that the results are “not fully mature”, with an analysis into overall survival benefit expected in the first half of 2018.

When announced alongside new data on the company’s haemophilia treatment Hemlibra – a therapy which just days ago scored US approval with the FDA – the news shook up share prices in the space, with haemophilia rivals Shire dropping 2% and AstraZeneca falling 0.5%, while Roche’s own shares rose by 5.6%.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches